At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 203 enrolled
Drug / intervention
CR845 +3 moredrug
Likely dose
CR845 0.04 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Double-Randomized, Double Blind, Placebo Controlled Study to Evaluate the Analgesic Efficacy and Safety of Intravenous CR845 Dosed Preoperatively and Postoperatively in Patients Undergoing a Laparoscopic Hysterectomy
In Brief
A Phase 2 clinical trial evaluating CR845 and Placebo for Postoperative Pain. Completed, enrolled 203 participants across 18 sites.
Detailed Summary
The primary purpose of this study is to determine if CR845 is effective in treating the pain associated with a laparoscopic hysterectomy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostoperative Pain
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2011
Enrollment StartJul 2011
Primary CompletionApr 2012
TodayJul 2026
First PostedMay 27, 2011
Enrollment StartJul 1, 2011
Primary CompletionApr 1, 2012
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 15.1 years ago
Interventions
CR845drug
Single i.v. dose (0.04 mg/kg) administered preoperatively
Placebodrug
Single i.v. dose administered preoperatively
CR845drug
Single i.v. dose (0.04 mg/kg) administered postoperatively for pain
Placebodrug
Single i.v. dose administered postoperatively for pain